<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00100607</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE581A2203</org_study_id>
    <nct_id>NCT00100607</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AAE581 in Postmenopausal Women With Osteoporosis</brief_title>
  <official_title>Safety and Efficacy of AAE581 in Postmenopausal Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will test the safety and efficacy of AAE581 in increasing Lumbar Spine bone
      mineral density (BMD) at 12 months, by Dexa-scan (DXA) in postmenopausal women with
      osteoporosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lumbar spine BMD and total hip BMD after 1 year treatment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of one year treatment with different doses</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of the different doses on BMD of lumbar spine, femoral neck, total hip, forearm and total body</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of the different doses on markers for bone formation and bone resorption</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural information on cortical and trabecular bone at different anatomic sites after 6 and 12 months of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological information on bone biopsy after 12 months of treatment</measure>
  </secondary_outcome>
  <enrollment type="Actual">676</enrollment>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AAE581</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMD T Score between -2 to -3.5

          -  50-75 years old

        Exclusion Criteria:

          -  Urolithiasis

          -  Bisphosphonates

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2005</study_first_submitted>
  <study_first_submitted_qc>January 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2005</study_first_posted>
  <last_update_submitted>May 7, 2012</last_update_submitted>
  <last_update_submitted_qc>May 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis/osteopenia, BMD, postmenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

